SUMMARY: Mu opioids, such as morphine, are effective analgesics, but their reward and tolerance drive opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance require the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced antinociceptive tolerance to morphine and fentanyl, without altering analgesia. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but markedly increased levels of m 6 Am on snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the role of m 6 Am in morphine reward and tolerance. We show that FTO depletion regulates a gene expression network linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants to mu opioids in pain management and treatment of opioid use disorder.
Buprenorphine has long been recognized as a mu opioid agonist with a distinctive and intricate pharmacological profile. It is a partial agonist at the mu opioid receptor, an antagonist at the kappa and delta opioid receptors, and an agonist at the nociception opioid receptor. Similar to other mu agonists such as morphine and fentanyl, buprenorphine can produce side effects, including tolerance, physical dependence, respiratory depression, and addiction. The mu opioid receptor gene, OPRM1, undergoes extensive alternative splicing, generating an array of splice variants or isoforms, which are conserved from rodents to humans. These splice variants can be categorized into 2 main types, exon 1 (E1)-associated variants and exon 11 (E11)-associated variants. E1-associated variants primarily consist of full-length, 7-transmembrane C-terminal variants, whereas E11-associated variants are typically truncated 6-transmembrane variants. Previous studies established that buprenorphine analgesia in mice is dependent on both E1- and E11-associated variants. However, the role of these variants in buprenorphine analgesia and respiratory depression in rats remains unclear. In this study, we used CRISPR/Cas9 technology to develop 2 rat Oprm1 gene-targeting models in which E1- and E11-associated variants were selectively disrupted, aiming to investigate their roles in buprenorphine and morphine's actions. The results showed that both E1- and E11-associated variants are essential for buprenorphine's analgesic and respiratory depressional effects in rats, whereas morphine's effects are solely attributed to the E1-associated variants. These findings provide new and important insights into the distinct contributions of the E1- and E11-associated variants to the pharmacological actions of buprenorphine and morphine. SIGNIFICANCE STATEMENT: Differential dependences of buprenorphine and morphine analgesia and respiratory depression on Oprm1 exon 1- and exon 11-associated variants revealed in rat gene-targeting models provide new and important insights into unique contributions of these variants to buprenorphine and morphine actions.
Mu opioids, such as morphine, are effective analgesics, but they produce reward and tolerance that lead to opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance are controlled by a reversible RNA modification in small nuclear RNA (snRNA) that is removed by the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced tolerance to morphine and fentanyl, without altering analgesia. Depleting Fto in the nucleus accumbens shell reduced reward but not tolerance, while depleting Fto in the dorsal root ganglion reduced tolerance but not reward, suggesting region-specific effects of FTO. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but a marked increase in m 6 Am levels in snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the importance of elevated m 6 Am in suppressing morphine reward and tolerance. Consistent with altered snRNA function, FTO depletion reshapes gene expression linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants for mu opioids in pain management and treatment of opioid use disorder.